NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Children's Oncology Group
The overall goal of this study is to test any good and bad effects of the study drug LOXO-101 (larotrectinib) on your tumor.